Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab vs Zoledronate in Osteopenic Patients With Lumbar Degenerative Disease After Lumbar Fusion Surgery
NCT05638399Phase 3Unknown
- Sponsor
- Shenzhen People's Hospital
- Start
- Jan 2020
- Primary completion
- Feb 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised trial of denosumab in osteopenia (2 arms), sponsored by Shenzhen People's Hospital. Primary endpoints: Lumbar bone mineral density at 12 months, Total hip bone mineral density at 12 months and 4 more. Status: unknown.
02
Drugs
denosumab
03
Conditions
osteopenia
Beyond the preview
Go deeper on NCT05638399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05638399.